The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
Open accessAbstract
Background Molecular characterization of nonmuscle invasive bladder cancer (NMIBC) may provide a biologic rationale for treatment response and novel therapeutic strategies. Objective To identify genetic alterations with potential clinical implications in NMIBC. Design, setting, and participants Pretreatment index tumors and matched germline DNA from 105 patients with NMIBC on a prospective Institutional Review Board-approved protocol underwent targeted exon sequencing analysis in a Clinical Laboratory Improvement Amendments-certified clinical laboratory. Outcome measurements and statistical analysis Comutation patterns and copy number alterations were compared across stage and grade. Associations between genomic alterations and recurrence after intravesical bacillus Calmette-Guérin (BCG) were estimated using Kaplan-Meier and Cox regression analyses. Results and limitations TERT promoter mutations (73%) and chromatin-modifying gene alterations (69%) were highly prevalent across grade and stage, suggesting these events occur early in tumorigenesis. ERBB2 or FGFR3 alterations were present in 57% of high-grade NMIBC tumors in a mutually exclusive pattern. DNA damage repair (DDR) gene alterations were seen in 30% (25/82) of high-grade NMIBC tumors, a rate similar to MIBC, and were associated with a higher mutational burden compared with tumors with intact DDR genes (p < 0.001). ARID1A mutations were associated with an increased risk of recurrence after BCG (hazard ratio = 3.14, 95% confidence interval: 1.51–6.51, p = 0.002). Conclusions Next-generation sequencing of treatment-naive index NMIBC tumors demonstrated that the majority of NMIBC tumors had at least one potentially actionable alteration that could serve as a target in rationally designed trials of intravesical or systemic therapy. DDR gene alterations were frequent in high-grade NMIBC and were associated with increased mutational load, which may have therapeutic implications for BCG immunotherapy and ongoing trials of systemic checkpoint inhibitors. ARID1A mutations were associated with an increased risk of recurrence after BCG therapy. Whether ARID1A mutations represent a predictive biomarker of BCG response or are prognostic in NMIBC patients warrants further investigation. Patient summary Analysis of frequently mutated genes in superficial bladder cancer suggests potential targets for personalized treatment and predictors of treatment response, and also may help develop noninvasive tumor detection tests.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766 · cited 1×
“Of the estimated 429 000 people to be diagnosed with bladder cancer in the industrialized world each year, 70–80% will have nonmuscle invasive bladder cancer (NMIBC) [1,2].”
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 3×
“Since mutational count is associated with response to systemic checkpoint inhibitor immunotherapy, we also examined the association between mutational count in NMIBC with recurrence after BCG immunotherapy [18].”
InfluentialSelf-citationComprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · cited 1×
“ARID1A mutations are associated with a poor prognosis in several cancers and have been shown to be associated with high-grade bladder cancer [25,26], but to our knowledge no prior study has examined the association between ARID1A mutations and BCG outcomes.”
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 808
The mechanism of action of BCG therapy for bladder cancer--a current perspective
Redelman-Sidi, G., Glickman, M. S., & Bochner, B. H. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.15 · Cited by 729
Self-citationSynthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., Schultz, D. C., Liu, Q., Shih, I.-M., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 678
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., Zhu, C., Ostrovnaya, I., Kryukov, G. V., O'Connor, K. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0623 · Cited by 620
Self-citationGuo, G., Sun, X., Chen, C., Wu, S., Huang, P., Li, Z., Dean, M., Huang, Y., Jia, W., Zhou, Q., et al. (2013) · Nature Genetics · doi:10.1038/ng.2798 · Cited by 482
Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer
Solomon, D. A., Kim, T., Diaz-Martinez, L. A., Fair, J., Elkahloun, A. G., Harris, B. T., Toretsky, J. A., Rosenberg, S. A., Shukla, N., Ladanyi, M., et al. (2011) · Science · doi:10.1126/science.1203619 · Cited by 436
Oncogenic FGFR3 gene fusions in bladder cancer
Williams, S. V., Hurst, C. D., & Knowles, M. A. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds486 · Cited by 390
van den Bosch, S., & Alfred Witjes, J. (2011) · European Urology · doi:10.1016/j.eururo.2011.05.045 · Cited by 382
Recurrence of high‐risk bladder cancer: A population‐based analysis
Chamie, K., Litwin, M. S., Bassett, J. C., Daskivich, T. J., Lai, J., Hanley, J. M., Konety, B. R., Saigal, C. S., & the Urologic Diseases in America Project (2013) · Cancer · doi:10.1002/cncr.28147 · Cited by 352
Genomic Characterization of Upper Tract Urothelial Carcinoma
Sfakianos, J. P., Cha, E. K., Iyer, G., Scott, S. N., Zabor, E. C., Shah, R. H., Ren, Q., Bagrodia, A., Kim, P. H., Hakimi, A. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.039 · Cited by 284
Self-citationAllory, Y., Beukers, W., Sagrera, A., Flández, M., Marqués, M., Márquez, M., van der Keur, K. A., Dyrskjot, L., Lurkin, I., Vermeij, M., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.08.052 · Cited by 284
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy
Balbás-Martínez, C., Sagrera, A., Carrillo-de-Santa-Pau, E., Earl, J., Márquez, M., Vazquez, M., Lapi, E., Castro-Giner, F., Beltran, S., Bayés, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2799 · Cited by 273
Stadler, Z. K., Battaglin, F., Middha, S., Hechtman, J. F., Tran, C., Cercek, A., Yaeger, R., Segal, N. H., Varghese, A. M., Reidy-Lagunes, D. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1067 · Cited by 234
Self-citationHurst, C. D., Platt, F. M., & Knowles, M. A. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.057 · Cited by 164
Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer
Nordentoft, I., Lamy, P., Birkenkamp‐Demtröder, K., Shumansky, K., Vang, S., Hornshøj, H., Juul, M., Villesen, P., Hedegaard, J., Roth, A. J. L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.038 · Cited by 159
Bártek, J., Lukas, J., & Bártková, J. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4754 · Cited by 154
Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder
Kim, P. H., Cha, E. K., Sfakianos, J. P., Iyer, G., Zabor, E. C., Scott, S. N., Ostrovnaya, I., Ramirez, R. J., Sun, A. J., Shah, R. H., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.06.050 · Cited by 153
Self-citationCazier, J., Rao, S. R., McLean, C. M., Walker, A. K., Wright, B. J., Jaeger, E., Kartsonaki, C., Marsden, L., Yau, C., Camps, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4756 · Cited by 117
Genomic characterization of response to chemoradiation in urothelial bladder cancer
Desai, N. B., Scott, S. N., Zabor, E. C., Cha, E. K., Hreiki, J., Sfakianos, J. P., Ramirez, R. J., Bagrodia, A., Rosenberg, J. E., Bajorin, D. F., et al. (2016) · Cancer · doi:10.1002/cncr.30219 · Cited by 63
Self-citationARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors
Balbás-Martínez, C., Rodriguez-Pinilla, M. S., Casanova, A., Domínguez, O., Pisano, D. G., Goméz-López, G., Lloreta, J., Lorente, J. A., Malats, N., & Real, F. X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062483 · Cited by 60
Zhou, X., Zhang, G., & Tian, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119476 · Cited by 20
Cited by
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
Self-citationAdvances in bladder cancer biology and therapy
Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 735
Fibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 352
Hurst, C. D., Alder, O., Platt, F. M., Droop, A., Stead, L. F., Burns, J. E., Burghel, G. J., Jain, S., Klimczak, L. J., Lindsay, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.005 · Cited by 311
Metadata
- Authors
- Pietzak, E. J., Bagrodia, A., Cha, E. K., Drill, E. N., Iyer, G., Isharwal, S., Ostrovnaya, I., Baez, P., Li, Q., Berger, M. F., Zehir, A., Schultz, N., Rosenberg, J. E., Bajorin, D. F., Dalbagni, G., Al-Ahmadie, H., Solit, D. B., & Bochner, B. H.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 72
- Issue
- 6
- Pages
- 952-959
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2621022579
- Cited by
- 373
- References
- 28
- FWCI
- 30.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.